COPENHAGEN, Denmark, December 9, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines ...

Evaxion Biotech (EVAX) has released an update. Evaxion Biotech, a clinical-stage company leveraging its AI-Immunology platform to create innovative vaccines, is set to announce its Q3 2024 ...

Evaxion Biotech (NASDAQ:EVAX) just reported results for the first quarter of 2024. Evaxion Biotech reported earnings per share of 3 cents. This was above the analyst estimate for EPS of -56 cents ...

As anticipated, Evaxion has received a delisting determination The determination has been appealed by Evaxion requesting a hearing on the matter and seeking another 180-day extension to comply ...

Evaxion Biotech (EVAX) will present preclinical Proof-of-Concept for its precision cancer vaccine concept, targeting non-conventional ERV tumor antigens shared across patients at the ESMO Immuno ...

With most of Evaxion’s strategic milestones for 2024 now successfully achieved, the company announces milestones for 2025 The 2025 key milestones reflect all parts of ...